Evidence map›Paper›PMID 34956887›Full record

ArticleFrontiers in oncology2021

Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway.

Namkyoung Kim, Injae Shin, Younghoon Kim, Eunhye Jeon, Jiwon Lee, Chaeyoung Lee, Yunju Nam, Sumin Lee, Eunhye Ju, Chan Kim and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Namkyoung KimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea.
Injae ShinKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea.
Younghoon KimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea.
Eunhye JeonSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Jiwon LeeSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Chaeyoung LeeSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Yunju NamKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea.
Sumin LeeSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Eunhye JuKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea.
Chan KimSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Woolim SonSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
SeongShick RyuKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea.
Minjoo KoSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Taebo SimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea.
Yonsei University · KRKorea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS mutants are involved in approximately 30% of all human cancers and have been regarded as undruggable targets owing to relatively smooth protein surface and obscure binding pockets. In our previous study, we have demonstrated that GNF-7, a multi-targeted kinase inhibitor, possesses potent anti-proliferative activity against Ba/F3 cells transformed with NRAS-G12D. Based on our further analysis using Ba/F3 cells transformed with mtRAS, we discovered a series of pyrimido[4,5-

Indexed as

cancers with mtRASGNF-7multi-targeted kinase inhibitormutated RASRAS signaling blockerRAS signaling pathway

Identifiers

PMID34956887
PMCPMC8695447
OpenAlexW4200054905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.